Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity
Authors
Keywords
-
Journal
PHARMACOLOGY
Volume 100, Issue 5-6, Pages 261-268
Publisher
S. Karger AG
Online
2017-08-11
DOI
10.1159/000477547
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Spironolactone: A selective androgen receptor modulator in castration-resistant prostate cancer.
- (2017) Philippe Barthelemy et al. JOURNAL OF CLINICAL ONCOLOGY
- Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer
- (2015) Consuelo Buttigliero et al. CANCER TREATMENT REVIEWS
- Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways
- (2015) HANNAH GROSSEBRUMMEL et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- What Do We Know About Steroids Metabolism and ‘PK/PD Approach' in AKI and CKD Especially While on RRT - Current Status in 2014
- (2014) Patrick M. Honoré et al. BLOOD PURIFICATION
- Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
- (2014) Dana E. Rathkopf et al. EUROPEAN UROLOGY
- Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone
- (2013) Anna Pia et al. CANCER TREATMENT REVIEWS
- PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
- (2013) Stephen Orena et al. Frontiers in Pharmacology
- Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100
- (2012) J. Richards et al. CANCER RESEARCH
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Abiraterone Acetate in the Management of Prostate Cancer: A Critical Analysis of the Literature
- (2011) Guru Sonpavde et al. EUROPEAN UROLOGY
- Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: An orally active anti-cancer drug waiting for its call-of-duty?
- (2011) Hayden Matthews et al. INTERNATIONAL JOURNAL OF CANCER
- Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer
- (2011) Gerhardt Attard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Noncanonical Wnt signaling mediates androgen-dependent tumor growth in a mouse model of prostate cancer
- (2011) S. Takahashi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Treatment of primary aldosteronism
- (2010) Marcus Quinkler et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now